SynthesisPloS one2025
Prevalence of metabolic syndrome among Iranian postmenopausal females: A systematic review and meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis systematic review and meta-analysis aimed to estimate the prevalence of metabolic syndrome (MetS) among Iranian postmenopausal women by addressing inconsistencies in prior research and providing reliable data to inform evidence-based policies for reducing Iran's MetS burden.
methodsMedline/PubMed, Scopus, Embase, Web of Science, Google Scholar, IMEMR, SID, MagIran, ISC, IranDoc/Ganj, Civilica, and RPIS were searched from their dates of inception until April 2025. The quality of the evidence was assessed using the Joanna Briggs Institute critical appraisal checklist. The prevalence of MetS was calculated using the random effects model using Stata version 17. Additionally, sensitivity analysis, subgroup analysis, meta-regression, and publication bias were assessed. The protocol is registered in PROSPERO, number CRD420251039469.
resultsA total of 24 papers were enrolled, comprising 17,281 postmenopausal participants with a pooled estimate of 58.42% (95%CI: 52.35-64.48, I2: 98.59%, Q: 836.97) MetS among Iranian postmenopausal females. The prevalence of MetS was 64.10%, 47.01%, 63.24%, and 50.16% in high-quality, medium-quality, population-based, and institutional-based studies, respectively. Moreover, meta-regression and subgroup analyses demonstrated study quality, study setting, and age as considerable sources of heterogeneity.
conclusionThis study highlights a high prevalence of MetS (≈58.5%) among Iranian postmenopausal women, with even greater estimates in high-quality and population-based studies, which underscores a significant public health concern. Given this substantial burden, routine screening for MetS components should be integrated into standard care for postmenopausal women, complemented by public health initiatives targeting lifestyle modifications and broader preventive strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.